ArticleBioinformatics (Oxford, England)2023
PPAD: a deep learning architecture to predict progression of Alzheimer's disease.
Article in Bioinformatics (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Frontotemporal dementia: a systematic review of artificial intelligence approaches in differential diagnosis.Frontiers in aging neuroscience · 2025Pooled it
- DyGraphTrans: A temporal graph representation learning framework for modeling disese progression from Electronic Health Records.bioRxiv : the preprint server for biology · 2026Article
- Evaluation of trajectory analysis for disease risk assessment: a scoping review.Journal of the American Medical Informatics Association : JAMIA · 2026Article
- A deep residual attention-Recurrent model for early and multi-stage Alzheimer's disease detection.Frontiers in aging neuroscience · 2026Article
- Artificial neural networks fighting real neural decline: a systematic review of AI in Alzheimer's research.Artificial intelligence review · 2026Article
- Flexible Multimodal Neuroimaging Fusion for Alzheimer's Disease Progression Prediction.Applications of medical artificial intelligence. AMAI (Workshop) (4th : 2024 : Taejon-si, Korea) · 2026Article
- A Hybrid Explainable AI Framework (HXAI) for Accurate and Interpretable Diagnosis of Alzheimer's Disease.Diagnostics (Basel, Switzerland) · 2025Article
- Intra-scale interaction and cross-scale fusion network for detecting the progression of neurodegeneration in Alzheimer's disease.Scientific reports · 2025Article
- NeuroNet-AD: A Multimodal Deep Learning Framework for Multiclass Alzheimer's Disease Diagnosis.Bioengineering (Basel, Switzerland) · 2025Article
- A Feature-Augmented Explainable Artificial Intelligence Model for Diagnosing Alzheimer's Disease from Multimodal Clinical and Neuroimaging Data.Diagnostics (Basel, Switzerland) · 2025Article
- A Meta-Learning-Based Ensemble Model for Explainable Alzheimer's Disease Diagnosis.Diagnostics (Basel, Switzerland) · 2025Article
- A Dynamic Model for Early Prediction of Alzheimer's Disease by Leveraging Graph Convolutional Networks and Tensor Algebra.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2025Article
- Identifying Alzheimer's disease-associated genes using PhenoGeneRanker.bioRxiv : the preprint server for biology · 2024Article
- Predicting Alzheimer's Cognitive Resilience Score: A Comparative Study of Machine Learning Models Using RNA-seq Data.bioRxiv : the preprint server for biology · 2024Article
- TA-RNN: an attention-based time-aware recurrent neural network architecture for electronic health records.Bioinformatics (Oxford, England) · 2024Article
- Multimodal Alzheimer's disease classification through ensemble deep random vector functional link neural network.PeerJ. Computer science · 2024Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
motivationAlzheimer's disease (AD) is a neurodegenerative disease that affects millions of people worldwide. Mild cognitive impairment (MCI) is an intermediary stage between cognitively normal state and AD. Not all people who have MCI convert to AD. The diagnosis of AD is made after significant symptoms of dementia such as short-term memory loss are already present. Since AD is currently an irreversible disease, diagnosis at the onset of the disease brings a huge burden on patients, their caregivers, and the healthcare sector. Thus, there is a crucial need to develop methods for the early prediction AD for patients who have MCI. Recurrent neural networks (RNN) have been successfully used to handle electronic health records (EHR) for predicting conversion from MCI to AD. However, RNN ignores irregular time intervals between successive events which occurs common in electronic health record data. In this study, we propose two deep learning architectures based on RNN, namely Predicting Progression of Alzheimer's Disease (PPAD) and PPAD-Autoencoder. PPAD and PPAD-Autoencoder are designed for early predicting conversion from MCI to AD at the next visit and multiple visits ahead for patients, respectively. To minimize the effect of the irregular time intervals between visits, we propose using age in each visit as an indicator of time change between successive visits.
resultsOur experimental results conducted on Alzheimer's Disease Neuroimaging Initiative and National Alzheimer's Coordinating Center datasets showed that our proposed models outperformed all baseline models for most prediction scenarios in terms of F2 and sensitivity. We also observed that the age feature was one of top features and was able to address irregular time interval problem. AVAILABILITY AND IMPLEMENTATION: https://github.com/bozdaglab/PPAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.